Lifeward Q4 revenue fell 33% to USD 5.08 million as net loss narrowed 65% to USD 5.35 million

Reuters03-18

Lifeward Q4 revenue fell 33% to USD 5.08 million as net loss narrowed 65% to USD 5.35 million

Lifeward published a quarterly and annual earnings press release reporting Q4 revenue of USD 5.08 million, down 33%, and FY revenue of USD 22.03 million, down 14%. Q4 gross margin was 21.4%, down 3 percentage points, while FY gross margin was 38.2%, up 6.2 percentage points. Q4 net loss was USD 5.35 million, down 65%, and FY net loss was USD 19.91 million, down 31%. In Q4, ReWalk Personal exoskeleton revenue rose 20% to USD 1.8 million on higher reimbursed unit sales, while AlterG revenue fell 43% to USD 3.2 million due to timing of orders from one international distributor expected to resume in 2026. Lifeward said it expects to close its strategic transaction with Oramed shortly after additional customary closing conditions are satisfied, and had USD 2.17 million of cash and cash equivalents as of Dec. 31, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifeward Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603180800PRIMZONEFULLFEED9674329) on March 18, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620535702?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-18 20:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620535702","market":"nz","top_or_hot":-1,"title":"Lifeward Q4 revenue fell 33% to USD 5.08 million as net loss narrowed 65% to USD 5.35 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lifeward Q4 revenue fell 33% to USD 5.08 million as net loss narrowed 65% to USD 5.35 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lifeward published a quarterly and annual earnings press release reporting Q4 revenue of USD 5.08 million, down 33%, and FY revenue of USD 22.03 million, down 14%. Q4 gross margin was 21.4%, down 3 percentage points, while FY gross margin was 38.2%, up 6.2 percentage points. Q4 net loss was USD 5.35 million, down 65%, and FY net loss was USD 19.91 million, down 31%. In Q4, ReWalk Personal exoskeleton revenue rose 20% to USD 1.8 million on higher reimbursed unit sales, while AlterG revenue fell 43% to USD 3.2 million due to timing of orders from one international distributor expected to resume in 2026. Lifeward said it expects to close its strategic transaction with Oramed shortly after additional customary closing conditions are satisfied, and had USD 2.17 million of cash and cash equivalents as of Dec. 31, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/LFWD\">Lifeward Ltd</a>. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603180800PRIMZONEFULLFEED9674329) on March 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lifeward Q4 revenue fell 33% to USD 5.08 million as net loss narrowed 65% to USD 5.35 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLifeward Q4 revenue fell 33% to USD 5.08 million as net loss narrowed 65% to USD 5.35 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-18 20:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lifeward Q4 revenue fell 33% to USD 5.08 million as net loss narrowed 65% to USD 5.35 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lifeward published a quarterly and annual earnings press release reporting Q4 revenue of USD 5.08 million, down 33%, and FY revenue of USD 22.03 million, down 14%. Q4 gross margin was 21.4%, down 3 percentage points, while FY gross margin was 38.2%, up 6.2 percentage points. Q4 net loss was USD 5.35 million, down 65%, and FY net loss was USD 19.91 million, down 31%. In Q4, ReWalk Personal exoskeleton revenue rose 20% to USD 1.8 million on higher reimbursed unit sales, while AlterG revenue fell 43% to USD 3.2 million due to timing of orders from one international distributor expected to resume in 2026. Lifeward said it expects to close its strategic transaction with Oramed shortly after additional customary closing conditions are satisfied, and had USD 2.17 million of cash and cash equivalents as of Dec. 31, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/LFWD\">Lifeward Ltd</a>. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603180800PRIMZONEFULLFEED9674329) on March 18, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL1n0shz:1","article_id":"2620535702","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620535702","pubTimestamp":1773835593,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lifeward published a quarterly and annual earnings press release reporting Q4 revenue of USD 5.08 million, down 33%, and FY revenue of USD 22.03 million, down 14%. Q4 gross margin was 21.4%, down 3 percentage points, while FY gross margin was 38.2%, up 6.2 percentage points. Q4 net loss was USD 5.35 million, down 65%, and FY net loss was USD 19.91 million, down 31%. In Q4, ReWalk Personal exoskeleton revenue rose 20% to USD 1.8 million on higher reimbursed unit sales, while AlterG revenue fell 43% to USD 3.2 million due to timing of orders from one international distributor expected to resume in 2026. Lifeward said it expects to close its strategic transaction with Oramed shortly after additional customary closing conditions are satisfied, and had USD 2.17 million of cash and cash equivalents as of Dec. 31, 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","NDAQ":"纳斯达克OMX交易所","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LFWD":"Lifeward Ltd","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","BK4588":"碎股","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4112":"金融交易所和数据","BK4082":"医疗保健设备","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4604":"机器人概念"},"translate_title":"Lifeward第四季度收入下降33%至508万美元，净亏损收窄65%至535万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"LFWD":0.9},"content_text":"Lifeward Q4 revenue fell 33% to USD 5.08 million as net loss narrowed 65% to USD 5.35 million\n    \n\n        Lifeward published a quarterly and annual earnings press release reporting Q4 revenue of USD 5.08 million, down 33%, and FY revenue of USD 22.03 million, down 14%. Q4 gross margin was 21.4%, down 3 percentage points, while FY gross margin was 38.2%, up 6.2 percentage points. Q4 net loss was USD 5.35 million, down 65%, and FY net loss was USD 19.91 million, down 31%. In Q4, ReWalk Personal exoskeleton revenue rose 20% to USD 1.8 million on higher reimbursed unit sales, while AlterG revenue fell 43% to USD 3.2 million due to timing of orders from one international distributor expected to resume in 2026. Lifeward said it expects to close its strategic transaction with Oramed shortly after additional customary closing conditions are satisfied, and had USD 2.17 million of cash and cash equivalents as of Dec. 31, 2025.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lifeward Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603180800PRIMZONEFULLFEED9674329) on March 18, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620535702","isCrawlerRequest":true}